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Abstract  
Osteosarcoma belongs tà the orphan diseases but is the most common primary malignant tumor 
of bone. Currently, the standard treatment for osteosarcoma requires both macroscopic surgical 
resection and postoperative multi-drug chemotherapy in neo-adjuvant and adjuvant settings. 
However, the 5-year event-free survival remains at a plateau of 60-70% of patients with 
non-metastatic osteosarcoma for over 30 years. Mifamurtide [liposomal muramyl tripeptide 
phosphatidylethanolamine (L-MTP-PE)] is a new agent. L-MTP-PE is a nonspecific 
immunomodulator, which is a synthetic analog of a component of bacterial cell walls. 
L-MTP-PE activates macrophages and monocytes as a potent activator of immune response. 
The addition of L-MTP-PE to standard chemotherapy improves the overall survival from 70 % 
to 78% and results in a one-third reduction in the risk of death from osteosarcoma. Recently, 
L-MTP-PE has been approved in Europe for the treatment of non-metastatic osteosarcoma with 
chemotherapy. According to preliminary clinical report, L-MTP-PE is well-tolerated and has 
little severe side effects. L-MTP-PE in combination with traditional treatment is expected to go 
mainstream and to be beneficial for patients with osteosarcoma. 
 
Key words osteosarcoma, liposomal muramyl tripeptide phosphatidylethanolamine, 
mifamurtide, macrophage, chemotherapy, innate immunity,  
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1. Introduction 
Osteosarcoma is the most common primary malignant bone tumor. It usually arises in the 
metaphyses of long bone in children and adolescents [1, 2]. Approximately 1000 new patients 
are seen per year in North America and a similar number in Europe [3]. The standard treatment 
of the primary osteosarcoma consists of macroscopic surgical resection and multi-agent 
chemotherapy in neo-adjuvant and adjuvant settings. Surgical techniques for osteosarcoma 
have improved and built up from amputations to limb-salvage surgery during the last decades 
[4]. However, it did not contribute to the improvement of both EFS and overall survival. 
On the other hand, the value of chemotherapy for treatment of osteosarcoma is well 
established [5, 6]. There are currently four chemotherapeutic agents, which consist of 
doxorubicin, cisplatin, high-dose methotrexate with leucovorin rescue, and ifosfamide [7-9]. 
Vigorous chemotherapy treatment with these agents has significantly improved survival of the 
osteosarcoma patients over the past several decades [10]. It has been reported that EFS of 
osteosarcoma patients at 3-5 years has reached 60-70% in the non-metastatic condition. 
However, that in the metastatic relapse or recurrent conditions remained at 10-30% since early 
1980s [4, 10-12]. None of the various chemotherapy agents and regimens has demonstrated any 
significant superiority yet [13]. No new anti-osteosarcoma agents have been developed in the 
intervening years [14]. Recently, Children’s Oncology Group carried out long-term follow-up 
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of the key trial of chemotherapy with or without mifamurtide (liposomal muramyl tripeptide 
phosphatidyl ethanolamine [L-MTP-PE]). The proprietary product name of mifamurtide is 
Mepact® (Takeda). This group demonstrated that addition of L-MTP-PE to chemotherapy 
significantly improved overall survival at 6 years from 70% with chemotherapy alone to 78 % 
with chemotherapy and L-MTP-PE (p = 0.03) [15]. These data demonstrate that L-MTP-PE 
may have a potential role in the improvement of survival of the osteosarcoma patients remained 
on a plateau for over two decades [14, 16-18]. L-MTP-PE, a nonspecific immunomodulator, is 
a synthetic analog of a component of bacterial cell walls [19]. L-MTP-PE activates 
macrophages and monocytes as a potent activator of immune response [20, 21].  
In this review, we will summarize the most recent findings about L-MTP-PE and its 
therapeutic application for non-metastatic osteosarcoma. 
 
2. Pharmacology  
MTP-PE is a stimulator of innate immunity and a synthetic molecule derived from muramyl 
dipeptide (MDP). MTP-PE results from the covalent addition of alanin and dipalmitoyl 
phosphatidyl ethanolamine to MDP (Figure 1), which is a peptidoglycan found in 
Gram-positive and Gram-negative bacterial cell walls [19].  
In vitro monocyte/macrophage activation by MTP-PE is related to the upregulation of 
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tumoricidal activity and secretion of pro-inflammatory cytokines including tumor necrosis 
factor (TNF)-α, interleukin (IL)-1, IL-6, IL-8, nitric oxide (NO), prostaglandin E2 (PGE2), and 
PGD2 [22-27]. NO, PGE2, and PGD2 are synthesized and released by murine Kupffer cells 
(liver macrophages) after in vitro MTP-PE exposure [28]. Moreover, L-MTP-PE induces the 
expression of adhesion molecules including lymphocyte function-associated antigen (LFA)-1, 
intracellular adhesion molecule (ICAM)-1, and human leukocyte antigen (HLA)-DR. These 
molecules could be closely related to interaction with tumor cells [19, 29]. 
MTP-PE is superior to MDP in the activation of human monocytes [20]. That is 
because the lipophilic properties of MTP-PE cause higher cell uptake via passive transfer 
through the cytoplasmic membrane. Indeed, the lipophilic MTP-PE could be efficiently 
incorporated in the lipid bilayer of liposomal structures and distributed primarily in the liver, 
spleen, and lungs after intravenous MTP-PE administration [20, 21, 30]. Thus, the intravenous 
MTP-PE encapsulated in liposomes has been developed to target delivery of the drug 
selectively to monocytes and macrophages, such as those in liver, spleen, and lungs [11, 14, 19]. 
These liposomes are composed of small lipid particles, which act as excellent transporters of 
lipophilic peptides [31]. The particle nature of liposomes converts the parent drug into 
“pro-drug”. Liposomes are concentric multi-lamellar vesicles with the lipid bilayers resembling 
an onion of particle size approximately 2-3 µm. Formulation of MTP-PE into these 
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phospholipid vesicles enhances the activation of macrophages/monocytes tumoricidal 
properties and extends its existence in the lungs [20, 30]. In fact, an advantage of MTP-PE over 
MDP in the activation of human monocytes was demonstrated [20]. This advantage was 
ascribed to the benefit of the lipophilic properties of MTP-PE described earlier. In addition, the 
liposomal formulation (L-MTP-PE) has improved the safety profile of several drugs by 
modifying parent drug or solubilization agent toxicity [32]. Due to rapid mononuclear 
phagocytosis of the liposome transporter, L-MTP-PE has very rapid clearance from the blood 
only approximately 0.5% of L-MTP-PE remains in the plasma at the 5-min time point 
compared with 93% when administrated as the free form [33]. In humans, there is no evidence 
of accumulation of either liposomes or free MTP-PE after L-MTP-PE 4-mg treatment twice a 
week for 9 week [34]. The half-life of free MTP-PE can be estimated as 3-6 h from dog and rat 
studies. Additionally, no accumulation of phospho1ipids after repeated administration has been 
confirmed [30]. Due to such the rapid clearance, L-MTP-PE shows ten times lesser adverse 
event level than free MTP-PE in rabbits and dogs [19]. 
MTP-PE can bind to Toll-like receptor (TLR) 4 and activate extracellular-signal 
regulated kinase 1/2 (ERK 1/2), nuclear factor-kappa B (NF-κB) and adaptor protein (AP)-1 
[27, 35]. However, the other receptor for MTP-PE may be intracellular [20]. Recently, MTP-PE 
has been reported as a specific ligand of nucleotide-binding oligomerization domain (Nod) 2 
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receptor. Nod2, an intracellular MDP sensor, is strongly expressed in monocytes, granulocytes, 
myeloid dendritic cells, and macrophages [36]. It induces NF-κB and influences the innate 
immune response [37]. L-MTP-PE is selectively phagocytosed by monocytes and macrophages 
after intravenous administration [38]. The phagocytic cells gradually degrade the liposomal 
vesicles. Then, MTP-PE is released into the cytosol where it interacts with Nod2 and activates 
the cells [20]. Thus, monocytes/macrophages activation by L-MTP-PE is considered to be 
mediated via Nod2 [14, 19] (Figure 2). In sum, preclinical studies showed that L-MTP-PE, in 
comparison with free MTP-PE, was more effective in terms of activating monocytes [20], was 
longer held in target organs [30], and was 10-fold less toxic [39].  
Monocytes activated by L-MTP-PE had no effect on non-tumorigenic cells [22, 24, 
40] and even under conditions of co-cultivation with tumorigenic cells [22, 40]. Furthermore, 
peripheral blood monocytes from patients with cancer could be activated to similar levels of 
tumoricidal activity as monocytes from healthy volunteers [24, 37, 40, 41]. L-MTP-PE interacts 
with interferon (IFN)-γ to up-regulate tumoricidal activity and to induce secretion of cytokines 
such as TNF-α and IL-1β [19, 42-47]. The mechanism of this potentiation remains to be 
elucidated, but a 2-fold increase in liposome phagocytosis was observed after treatment of 
human monocytes with IFN-γ  [47]. 
Activation of monocytes-mediated tumoricidal activity was investigated following in 
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vivo treatment with L-MTP-PE in phase I and II clinical trials [34, 48, 49]. In the phase I study, 
28 patients with metastatic cancer received increasing doses (1h intravenous administration) of 
L-MTP-PE (0.05-12.0 mg/m2) twice a week [34, 48]. Peripheral blood monocytes were 
harvested and examined ex vivo for cytotoxic activity against human A375 melanoma cells 
before L-MTP-PE therapy and at various time points during the 9-week treatment period. 
Activation of monocytes-mediated cytotoxic activity was seen in 24 (86%) of the 28 patients at 
some time points during the treatment period [48]. Monocytes-mediated tumoricidal activity 
remained for up to 96 hours after initial mifamurtide infusion [34]. In the phase II study, 16 
patients with relapsed osteosarcoma received a 1h intravenous infusion of L-MTP-PE (2 
mg/m2) twice a week for 12 weeks [49]. These patients had histologically confirmed 
osteosarcoma and pulmonary metastases that had developed during adjuvant chemotherapy or 
that were present at diagnosis and had persisted despite chemotherapy. The patients were 
pre-treated with surgical resection of visible and palpable lung metastases before participating 
in the study. Peripheral blood monocytes were harvested and examined ex vivo for cytotoxic 
activity against human A375 melanoma cells before L-MTP-PE therapy and during the 4-week 
treatment period. Monocytes-mediated tumoricidal activity was significantly increased in 80% 
of the patients evaluated. The peak cytotoxic activity was observed at 24 (n = 3), 72 (n = 4), and 
96 (n = 1) hours post-infusion [49]. Similarly, monocytes and macrophages from non-human 
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species demonstrated increased tumoricidal activity after in vitro [23, 26] and in vivo [26, 43, 
50-52] treatment with L-MTP-PE or MTP-PE.       
Although various chemotherapeutic agents and regimens have been examined for 
osteosarcoma, none of them demonstrates any clear superiority [13, 53]. Since L-MTP-PE was 
intended to be used in combination with adjuvant chemotherapy to surgery in the treatment of 
osteosarcoma, some researchers reported the effects of cytotoxic agents on the 
monocytes-mediated tumoricidal activity of L-MTP-PE [37, 54, 55]. These results showed that 
most chemotherapeutic drugs including the treatment of osteosarcoma (i.e., doxorubicin, 
cisplatin, high-dose methotrexate with leucovorin rescue, and ifosfamide) did not influence on 
macrophage activation by L-MTP-PE [37, 54, 55].  For example, doxorubicin [37, 54], cisplatin 
[37], methotrexate [37], or cyclophosphamide [37] administration to patients with 
osteosarcoma did not interfere with the ability of L-MTP-PE to enhance the 
monocytes-mediated tumoricidal activity from these patients in vitro. Furthermore, 
combination chemotherapy of doxorubicin and cyclophosphamide strongly suppressed 
monocytes-mediated tumoricidal activity by L-MTP-PE [37]. Similarly, simultaneous 
administration of ifosfamide and L-MTP-PE did not interfere with the ability of L-MTP-PE to 
activate an in vivo immune response according to the results of a phase IIb clinical study in 
patients with relapsed osteosarcoma (n = 9) [55]. The trial participants had histologically 
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confirmed osteosarcoma and pulmonary metastases that had developed during adjuvant 
chemotherapy or that were present at diagnosis and had persisted despite chemotherapy. They 
were treated neoadjuvantly and/or adjuvantly with a combination of ifosfamide ( up to 8 cycles 
in total; each cycle consisted of 1.8 g/m2 for 5 days every 21 days) and L-MTP-PE (2 mg/m2 
twice a week for 12 weeks and then once a week for 12 weeks). Up-regulations of serum TNF-α, 
IL-6, and IL-8 in patients treated with the combination therapy was not different from those in 
patients treated with L-MTP-PE alone [49]. In addition, monocytes-mediated tumoricidal 
activity was elevated at 24 and 72 hours after the initial of combination therapy, similar to the 
following L-MTP-PE alone [48]. In particular, combination treatment of ifosfamide and 
L-MTP-PE did not increase the toxicity of ifosfamide [55]. L-MTP-PE did not decrease the 
tumoricidal activity of ifosfamide or doxorubicin in three synergistic murine tumor models [56]. 
Furthermore, the suggested course of L-MTP-PE therapy did not worsen the identified renal 
(i.e., cisplatin, ifosfamide) or hepatic (i.e., methotrexate, ifosfamide) toxicities of the 
concurrently administered chemotherapies in phase III study in patients with osteosarcoma 
[57].   
3. Clinical therapeutic efficacy  
A phase III randomized prospective trial was conducted by the Children’s Cancer and Pediatric 
Oncology Groups (now collectively known as the Children’s Oncology Group) from 1993 to 
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1997 [10]. This central randomized trial in osteosarcoma, known as the Intergroup Study 0133 
(INT study 0133), was recruited a total of 662 eligible patients aged ≤ 30 years with 
non-metastatic osteosarcoma whose primary tumors were considered to be resectable [15]. This 
study was designed to assess whether the addition of L-MTP-PE and/or ifosfamide to a 
standard chemotherapeutic regimen composed of three agents (i.e., doxorubicin, cisplatin and 
high-dose methotrexate with leucovorin rescue) would increase both EFS and overall survival 
in newly diagnosed patients with high-grade osteosarcoma. No significant improvement in EFS 
and overall survival was observed by the addition of ifosfamide in the dose and schedule used 
in this study (p = 0.934 and 0.992 respectively). However, significant improvement in EFS and 
overall survival were observed in patients randomized to receive L-MTP-PE (p = 0.030 and 
0.039 respectively). These findings correspond to a 25% reduction in the risk of recurrence and 
a 30% reduction in the risk of death [19, 58]. Most notably, the 6-year overall survival 
improved from 70% without L-MTP-PE to 78% with it [15]. 
In the INT study 0133, all patients were intended to receive a similar backbone 
treatment called MAP (i.e., high-dose methotrexate with leucovorin rescue, 
doxorubicin/adriamycin, and cisplatin) with identical cumulative doses of high-dose 
methotrexate (12 times at doses of 12 g/m2), doxorubicin (6 times at doses of 75 mg/m2), and 
cisplatin (4 times at doses of 120 mg/m2). The randomized prospective study was conducted 
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with a 2 × 2 factorial design with 4 treatment groups: (1) MAP, (2) MAP + L-MTP-PE, (3) 
MAP + ifosfamide, and (4) MAP + ifosfamide + L-MTP-PE. Ifosfamide was administered 5 
times at a dose of 9 g/m2 per course. L-MTP-PE was administered at a dose of 2 mg/m2 
basically. L-MTP-PE was administered intravenously twice a week for 12 weeks starting at 
week 12, and then weekly for additional 24 weeks starting at week 24. The duration of 
treatment was 20 weeks for patients randomly assigned to ‘MAP’ group, 27 weeks for patients 
randomly assigned to ‘MAP + ifosfamide’ group, and 36 weeks for patients randomly assigned 
to ‘MAP + L-MTP-PE’ group and ‘MAP + ifosfamide + L-MTP-PE’ [10, 15]. The results of 
INT study 0133 were analyzed and published in 2005 and 2008 [10, 15]. In 2005, Meyers et al. 
[10] reported their initial analysis of EFS without overall survival. According to their findings, 
there was no significant evidence of L-MTP-PE on EFS [10]. Later, this initial report was cited 
as inappropriate analyses. In 2008, as the subsequent analysis with longer follow-up, both 
overall survival and EFS were reported as the end points of the study [15]. This re-analysis 
reported improved overall survival with the addition of L-MTP-PE from 70% to 78% 6-year 
overall survival (p = 0.03) [15]. By contrast, in the analysis of EFS, there was no sufficient 
evidence of the interaction (p = 0.102) [15]. This makes the interpretation of INT 0133 study 
very complicated [59, 60] because the effect of treatment on overall survival is expected to be 
mediated through EFS. There were no differences in the frequency of favorable tumor necrosis, 
13 
 
which is strongly associated with EFS and determined by modified Huvos grading [61], among 
those treatment groups. Therefore, the authors concluded that ifosfamide and the other 
chemotherapy agents are equivalent in their ability to contribute to favorable tumor necrosis. 
Furthermore, another study demonstrated that patients with metastatic osteosarcoma were 
given a good benefit by administration of a higher dose of ifosfamide (14 mg/m2) [62, 63] . 
Thus, the most effective combination of ifosfamide with L-MTP-PE may be a dose question. At 
any rate, many additional questions including the best way to combine chemotherapy and 
L-MTP-PE still remain, but the INT study 0133 clearly demonstrated the clinical benefit 
associated with L-MTP-PE in the treatment of osteosarcoma.  
 
4. Dosage and Side effects 
In European Union, L-MTP-PE is indicated in patients with high-grade, resectable, 
non-metastatic osteosarcoma after macroscopically complete surgical resection aged between 2 
and 30 years [57]. It is currently recommended that L-MTP-PE is intravenously-administered 
over 1 hour twice weekly for an initial 12 weeks, followed by once weekly for an additional 24 
weeks (total 48 infusions in 36 weeks) [15]. Since all patients recently receiving L-MTP-PE on 
a compassionate basis have had evidence of biologic activity at 2 mg/m2, premedication and use 
of the fixed 2 mg/m2 dose is suggested. The preparation and infusion of L-MTP-PE has recently 
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been validated in numerous processes, and these are reproducible and easily performed in the 
outpatient setting. 
L-MTP-PE therapy was generally well tolerated [34, 64]. The most commonly 
reported side effects are listed in Figure 3. Most of those side effects were mild or moderate 
severity [57]. In the phase I and II studies, there was no evidence of dose-dependent [65], 
cumulative [34], and organ-related [65] toxicity in association with L-MTP-PE. Furthermore, 
the majority of patients experienced side effects with the initial administration of the agent [34, 
66]. The major side effects of L-MTP-PE administration are fever and chills. They are typically 
transient and generally respond to palliative treatment [57]. The possibility of 
anti-inflammatory drugs relieving these adverse effects has been investigated. Premedication 
such as ibuprofen [67] can help prevent the severity of fever and chills. However, high-dose 
ibuprofen (> 40 µg/ml) with L-MTP-PE down-regulates the antitumor effect and the production 
of IL-1 and TNF-α in monocytes [67]. The antitumor effect of L-MTP-PE was lost in a murine 
fibrosarcoma model using diclofenac [68]. These findings suggest that anti-inflammatory 
agents such as cyclooxygenase inhibitors can down-regulate the antitumor effect of L-MTP-PE. 
For ibuprofen-resistant cases, acetaminophen and/or meperidine are recommended as 
alternative agents [11]. Specifically, ibuprofen 200 or 400 mg is given as a premedication, If 
fever and/or chills occur, acetaminophen (15 mg/kg; up to 1000mg) may be given. If needed 
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more, both acetaminophen and ibuprofen may be additionally utilized to improve the symptoms 
[15, 69]. 
 
5. Expert Opinion 
The orphan disease limits the number of patients available to study. Osteosarcoma is 
an orphan disease with fewer than 1500-2000 new cases per year diagnosed in the USA similar 
to Europe. Indeed, except L-MTP-PE, only IFN-α study are undergoing as international 
cooperative trial for osteosarcoma adjuvant chemotherapy. The efficacy of IFN-α, which is 
initiated after postoperative chemotherapy, is investigated by EURAMOS 1 [38]. 
Unfortunately, this trial is still under the recruitment phase [17]. Therefore, L-MTP-PE, the first 
new agent approval for the treatment of osteosarcoma in over 20 years, is strongly expected to 
become ‘routine’ for both oncologists and patients with osteosarcoma. From now on, this will 
require future international prospective trials of L-MTP-PE in osteosarcoma treatment. 
 
Figure legends 
Figure 1: The molecular structure of liposomal muramyl tripeptide phosphatidyl ethanolamine 
(L-MTP-PE). 
Figure 2: Nod2 is an intracellular MDP sensor. Monocytes/macrophages activation by 
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L-MTP-PE is mediated via Nod2. L-MTP-PE is selectively phagocyted by monocytes and 
macrophages after intravenous administration. L-MTP-PE is released into the cytosol and 
degraded to MDP. Nod2 binding to MDP activates NF-κB and influences the innate immune 
response. Abbreviations: Nod2; nucleotide-binding oligomerization domain 2, MDP; muramyl 
dipeptide, L-MTP-PE; liposomal muramyl tripeptide phosphatidyl ethanolamine, NF-κB; 
nuclear factor-kappa B. 
Figure 3: Tolerability of mifamurtide. Major side effects in 248 patients with advanced cancer 
including 51 patients with osteosarcoma [34, 57, 64-66]. 
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